Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

European Journal of Cancer

Volumn 81, Issue , 2017, Pages 116-129

  Emens, Leisha A ^a   Ascierto, Paolo A ^b   Darcy, Phillip K ^c,d   Demaria, Sandra ^e   Eggermont, Alexander M M ^f   Redmond, William L ^g   Seliger, Barbara ^h   Marincola, Francesco M ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g EARLE A CHILES RESEARCH INSTITUTE   (United States)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Cancer immunotherapy; Cytotoxic T lymphocyte antigen 4 (CTLA 4); Immune checkpoint blockade; Programmed death ligand 1 (PD L1); Programmed death 1 (PD 1); Tumour immunity

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC DISEASE; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85020514166     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.035     Document Type: Review

References (135)

1. [1] Lipson, E.J., Forde, P.M., Hammers, H.J., Emens, L.A., Taube, J.M., Topalian, S.L., Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 42 (2015), 587–600.
2. [2] McCarthy, E.F., The toxins of William B. Coley and the treatment of bone and soft tissue sarcomas. Iowa Orthop J 26 (2006), 154–158.
3. [3] Ehrlich, P., Uber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 5 (1909), 273–290.
4. [4] Corthay, A., Does the immune system naturally protect against cancer?. Front Immunol, 5, 2014, 197, 10.3389/fimmu.2014.00197 eCollection 2014.
5. [5] Prehn, R.T., Main, J.M., Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18 (1957), 769–778.
6. [6] Lum, B.L., Torti, F.M., Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 83 (1991), 682–694.
7. [7] Floros, T., Tarhini, A.A., Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol 42 (2015), 539–548.
8. [8] Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002), 991–998.
9. [9] Future II Study Group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007), 1915–1927.
10. [10] Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 (2010), 411–422.
11. [11] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
12. [12] Robert, C., Ribas, A., Wolchok, J.D., Hodi, F.S., Hamid, O., Kefford, R., et al. Anti-programmed death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
13. [13] Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
14. [14] Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., et al. Targeted therapy with the T cell engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29 (2011), 2493–2498.
15. [15] Andtbacka, T.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33 (2015), 2780–2788.
16. [16] Chen, D.S., Mellman, I., Oncology meet immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
17. [17] Ascierto, P.A., Marincola, F.M., What have we learned from cancer immunotherapy in the last 3 years?. J Transl Med, 12, 2014, 141.
18. [18] Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
19. [19] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammer, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
20. [20] Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbe, C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
21. [21] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
22. [22] McDermott, D.F., Drake, C.G., Sznol, M., Choueiri, T.K., Powderly, J.D., Smith, D.C., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol, 33, 2013-2030.
23. [23] Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
24. [24] Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
25. [25] Hodi, F.S., Chesney, J., Pavlick, A.C., Robert, C., Grossman, K.F., McDermott, D.F., et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17 (2016), 1558–1568.
26. [26] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
27. [27] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, A., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
28. [28] Hodi, F.S., Postow, M.A., Chesney, J.A., Pavlick, A.C., Robert, C., Grossman, K.F., et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CehckMate 069). J Clin Oncol, 34(suppl: abstr 9518), 2016.
29. [29] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
30. [30] Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (Checkmate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
31. [31] Hodi, F.S., Hwu, W.J., Kefford, R., Weber, J.S., Daud, A., Hamid, O., et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34 (2016), 1510–1517.
32. [32] Maio, M., Danielli, R., Chiarion-Sileni, V., Pigozzo, J., Parmiani, G., Ridolfi, R., et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 24 (2013), 2911–2915.
33. [33] Luke, J.J., Callahan, M.K., Postow, M.A., Romano, E., Ramaiya, N., Bluth, M., et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the DFCl, MGH, MSKCC, and UHL experience. Cancer 119 (2013), 3687–3695.
34. [34] Kelderman, S., vander Kooij, M.K., van den Eertwegh, A.J., Soetekouw, P.M., Jansen, R.L., van den Brom, R.R., et al. Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch working group on immunotherapy of oncology (WIN-O). Acta Oncol 52 (2013), 1786–1788.
35. [35] Zimmer, L., Vaubel, J., Morh, P., Hauschild, A., Utikal, J., Simon, J., et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One, 10, 2015, e0118564.
36. [36] Del Vecchio, M., Di Guardo, L., Ascierto, P.A., Grimaldi, A.M., Sileni, V.C., Pigozzo, J., et al. Efficacy and safety of ipiliumumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 50 (2014), 121–127.
37. [37] Postow, M.A., Ott, P.A., Callahan, M.K., Harding, J.J., D'Angelo, S.P., Dickson, M.A., et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 18 (2013), 726–732.
38. [38] Ascierto, P.A., Simeone, E., Sileni, V.C., Pigozzo, J., Maio, M., Altomonte, M., et al. Clinical experience with ipilimumab 3 mg/kg: real-work efficacy and safety data from an expanded access programme cohort. J Transl Med, 12, 2014, 116.
39. [39] Ascierto, P.A., Addeo, R., Carteni, G., Daniele, B., De Laurentis, M., Ianneillo, G.P., et al. The role of immunotherapy in solid tumors: report of the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med, 12, 2014, 291.
40. [40] Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F.L., Carbonnel, F., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13 (2016), 473–486.
41. [41] Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
42. [42] Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossman, K., McDermott, D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
43. [43] Long, G.V., Atkinson, V., Cebon, J.S., Jameson, M.B., Fitzharris, B.M., McNeil, C.M., et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J Clin Oncol, 24, 2016 suppl abstr 9506.
44. [44] Hellman, M.D., Gettinger, S.N., Goldman, J., Brahmer, J., Borghaei, H., Chow, L.W., et al. CheckMate 012: safety and efficacy of first-line nivolumab and ipilumumab in advanced NSCLC. J Clin Oncol, 34, 2016 (suppl; abstr 3001).
45. [45] Emens, L.A., Middleton, G., The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3 (2015), 436–443.
46. [46] Lynch, T.J., Bondarenko, I., Luft, A., Servatowshi, P., Barlesi, F., Chacko, R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 30 (2012), 2046–2054.
47. [47] Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24 (2013), 75–85.
48. [48] Langer, C.J., Gadjeel, S.M., Borgheai, H., Papadimitrakopolou, V.A., Patanaik, A., Powell, S.F., et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol, 2016, 10.1016/S1470-2045(16)30498-3.
49. [49] Formenti, S.C., Demaria, S., Systemic effects of local radiotherapy. Lancet Oncol 10 (2009), 718–726.
50. [50] Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
51. [51] Demaria, S., Golden, E.B., Formenti, S.C., Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1 (2016), 1325–1332.
52. [52] Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14 (2007), 1848–1850.
53. [53] Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, A., Ortiz, C., Criollo, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007), 1050–1059.
54. [54] Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852.
55. [55] Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T.O., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181 (2008), 3099–3107.
56. [56] Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., Lord, E.M., Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174 (2005), 7516–7523.
57. [57] Lugade, A.A., Sorensen, E.W., Gerber, S.A., Moran, J.P., Frelinger, J.G., Lord, E.M., Radiation-induced IFN-gamma production enhances MHC class I expression, and induces successful antitumor immunotherapy. J Immunol 180 (2008), 3132–3139.
58. [58] Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 (2006), 1259–1271.
59. [59] Chakraborty, M., Abrams, S.I., Camphausen, K., Lui, K., Scott, T., Coleman, C.N., et al. Irradiation of tumor cell up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170 (2003), 6338–6347.
60. [60] Garnett, C.T., Palena, C., Chakarborty, M., Tsang, K.Y., Schlom, J., Hodge, J.W., Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64 (2004), 7985–7994.
61. [61] Ruocco, M.G., Pilones, K.A., Kawashima, N., Cammer, M., Huang, J., Babb, J.S., et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves anti-tumor effects. J Clin Invest 122 (2012), 3718–3730.
62. [62] Filatenov, A., Baker, J., Mueller, A.M., Kenkel, J., Ahn, G.O., Dutt, S., et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete responses. Clin Cancer Res 21 (2015), 3727–3739.
63. [63] Demaria, S., Formenti, S.C., Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol, 2, 2012, 153.
64. [64] Dewan, M.Z., Vanpouille-Box, C., Kawashima, N., DiNapoli, S., Babb, J.S., Formenti, S.C., et al. Synergy of topical toll-like receptor-7 agonist with radiation and low dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 18 (2012), 6668–6678.
65. [65] Demaria, S., Coleman, S.N., Formenti, S.C., Radiotherapy: changing the game in immunotherapy. Trends Cancer 2 (2016), 286–294.
66. [66] Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15 (2014), 700–712.
67. [67] Golden, E.B., Demaria, S., Schiff, P.B., Chachoua, A., Formenti, S.C., An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1 (2013), 365–372.
68. [68] Golden, E.B., Chachoua, A., Fenton-Kermian, M.G., Demaria, S., Formenti, S.C., Abscopal responses in metastatic non-small cell lung cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and ipilimumab: evidence for the in situ vaccination hypothesis of radiation. Int J Radiat Oncol Biophys 93 (2015), S66–S67.
69. [69] Brody, J.D., Ai, W.Z., Czerwinski, D.K., Torshia, J.A., Levy, M., Advani, R.H., et al. In situ vaccination with a TLR-9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28 (2010), 4324–4332.
70. [70] Golden, E.B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumors: a proof of principle trial. Lancet Oncol 16 (2015), 795–803.
71. [71] Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C., Blum, E.H., Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996), 7–17.
72. [72] Grob, J.J., Dreno, B., de la Salmoniere, P., Delaunay, M., Cupissol, D., Guillot, B., et al. Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (1998), 1905–1910.
73. [73] Eggermont, A.M., Suciu, S., Santianami, M., Testori, A., Kruit, W.H., Marden, J., et al. Adjuvant therapy with pegylated interferon alpha 2b versus observation alone in resected stage II melanoma: final results of EORTC 18991: a randomised phase III trial. Lancet 372 (2008), 117–126.
74. [74] Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., Suciu, S., Does adjuvant interferon alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29 (2003), 241–252.
75. [75] Mocellin, S., Pasquali, S., Rossi, C.R., Nitti, D., Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102 (2010), 43–501.
76. [76] Eggermont, A.M., Suciu, S., Testori, A., Patel, P., Spatz, A., EORTC Melanoma Group. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48 (2012), 218–225.
77. [77] Eggermont, A.M., Suciu, S., Testori, A., Sanitanami, M., Kruit, W.H., Marsden, J., et al. Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30 (2012), 3810–3818.
78. [78] Eggermont, A.M., Suciu, S., Rutkowski, P., Kruit, W.H., Punt, C.J., Dummer, R., et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 55 (2016 Mar), 111–121.
79. [79] Suciu, S., Ives, N., Eggermont, A.M., Kirkwood, J.M., Lorigan, P., Markovic, S., et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). J Clin Oncol, 32(5s), 2014, 9067.
80. [80] Eggermont, A.M., Therapeutic vaccines in solid tumors: can they be harmful?. Eur J Cancer 45 (2009), 2087–2090.
81. [81] Eggermont, A.M., Suciu, S., Rutkowski, P., Marsden, J., Santiami, M., Corrie, P., et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor >1.5mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31 (2013), 3831–3837.
82. [82] Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.
83. [83] Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375 (2016), 1845–1855.
84. [84] Eggermont, A.M., Adjuvant ipilimumab in stage III melanoma: new landscape, new questions. Eur J Cancer 69 (2016), 39–42.
85. [85] Wolchok, J.D., Neyns, B., Linette, B., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
86. [86] Ascierto, P.A., del Vecchio, M., Robert, C., Mackiewicz, A., Chiaron-Sileni, V., Arance, A.M., et al. Overall survival (OS) and safety results from a phase 3 trial of ipiliumumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL). Ann Oncol 27suppl:6 (2016), v379–400.
87. [87] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
88. [88] Flaherty, K.T., Hennig, M., Lee, S.J., Ascierto, P.A., Dummer, R., Eggermont, A.M., et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 15 (2014), 297–304.
89. [89] Korn, E.L., Liu, P.Y., Lee, S.J., Chapman, J.A., Niedzwiecki, D., Suman, V.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26 (2008), 527–534.
90. [90] Daud, A., Ribas, A., Robert, C., Hodi, F.S., Wolchok, J.D., Joshua, A.M., et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO Meet Abstr, 33, 2015, 9005.
91. [91] Ascierto, P.A., Long, G.V., Progression-free survival landmark analysis: a critical endpoint in clinical trials of drug therapies in patients with advanced melanoma. Lancet Oncol 17 (2016), 1037–1039.
92. [92] Van der Burg, S.H., Arens, R., Ossendorp, F., van Hall, T., Melief, C.J., Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16 (2016), 219–233.
93. [93] Lesokhin, A.M., Callahan, M.K., Postow, M.A., Wolchok, J.D., On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med, 7, 2015, 280sr1.
94. [94] Schietinger, A., Greenberg, P.D., Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35 (2014), 51–60.
95. [95] Redmond, W.L., Sherman, L.A., Peripheral tolerance of CD8 T lymphocytes. Immunity 22 (2005), 275–284.
96. [96] Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med, 8, 2016, 328rv4.
97. [97] Yuan, J., Hegde, P.S., Clynes, R., Foukas, P.G., Harari, A., Kleen, T.O., et al. Novel technologies and emerging biomarkers for personalized immunotherapy. J Immunother Cancer, 4, 2016, 3.
98. [98] Dubin, K., Callahan, M.K., Ren, B., Khanin, R., Viale, A., Ling, L., et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun, 7, 2016, 10391.
99. [99] Callahan, M.K., Wolchok, J.D., Clinical activity, toxicity, biomarkers, and future development of CTLA-4 checkpoint antagonists. Semin Oncol 42 (2015), 573–586.
100. [100] Leone, P., Shin, E.C., Perosa, F., Vacca, A., Dammacco, F., Racanelli, V., MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 105 (2013), 1172–1187.
101. [101] Bukur, J., Jasinski, S., Seliger, B., The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 22 (2012), 350–358.
102. [102] Hermann, F., Lehr, H.A., Drexler, I., Sutter, G., Hengstler, J., Wollscheid, U., et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64 (2004), 215–220.
103. [103] Carretero, R., Romero, J.M., Ruiz-Cabello, F., Maleno, I., Rodriguez, F., Camacho, F.M., et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60 (2008), 439–447.
104. [104] Strannegard, O., Thoren, F.B., Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha—can tumor immune escape after immunotherapy accelerate disease progression?. Oncoimmunology, 5, 2015, e1091147.
105. [105] Jasinski-Bergner, S., Reches, A., Stoehr, C., Massa, C., Gonschorek, E., Huettelmaier, S., et al. Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget 7 (2016), 26866–28678.
106. [106] Kochan, G., Escors, D., Breckpot, K., Guerrero-Setas, D., Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology, 2, 2013, e26491.
107. [107] Lee, S., Park, H.Y., Kang, S.Y., Kim, S.J., Hwang, J., Lee, S., et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget 6 (2015), 17764–17776.
108. [108] Leibowitz, M.S., Andrade Filho, P.A., Ferrone, S., Ferris, R.L., Deficiency of activated STAT1 in head and neck cancer cells mediates TAP-1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 60 (2011), 525–535.
109. [109] Lopez, C., Bergmann, A.K., Paul, U., Murga Penas, E.M., Nagel, I., Betts, M.J., et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol 173 (2016), 265–273.
110. [110] Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375 (2016), 819–829.
111. [111] Setiadi, A.F., Omilusik, K., David, M.D., Seipp, R.P., Hartikainen, J., Gopaul, R., et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68 (2008), 9601–9607.
112. [112] Vikova, V., Stepanek, I., Hruskova, V., Senigl, F., Mayerova, V., Sramek, M., et al. Epigenetic regulation in the IFNg signaling pathway: IFNg-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes. Oncotarget 5 (2014), 6923–6935.
113. [113] Ramsuran, V., Kulkarni, S., O'huigin, C., Yuki, Y., Augusto, D.G., Gao, X., et al. Epigenetic regulation of differential HLA-A allelic expression levels. Hum Mol Genet 24 (2015), 4268–4275.
114. [114] Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
115. [115] Galon, J., Mlecnik, B., Bindea, G., Angell, H.K., Berger, A., Lagorce, C., et al. Towards the introduction of the “immunoscore” in the classification of malignant tumors. J Pathol 232 (2014), 199–209.
116. [116] Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005), 2654–2666.
117. [117] Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29 (2011), 610–618.
118. [118] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
119. [119] Mlecnik, B., Bindea, G., Angell, H.K., Maby, P., Angelova, M., Tougeron, D., et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44 (2016), 698–711.
120. [120] Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
121. [121] Socinskci, M., Creelan, B., Horn, L., Reck, M., Paz-Ares, L., Steins, M., et al. CheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol, 27, 2016 suppl 6: LBA PR7.
122. [122] Allard, B., Pommey, S., Smyth, M.J., Stagg, J., Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19 (2013), 5626–5635.
123. [123] Beavis, P.A., Milenkovski, N., Henderson, M.A., John, L.B., Allard, B., Loi, S., et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3 (2015), 506–517.
124. [124] Waickman, A.T., Alme, A., Senaldi, L., Zarek, P.E., Horton, M., Powell, J.D., Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 61 (2011), 917–926.
125. [125] Godin-Ethier, J., Hanafi, L.A., Piccirillo, C.A., Lapointe, R., Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17 (2011), 6985–6991.
126. [126] Gangadhar, T.C., Hamid, O., Smith, D.C., Bauer, T.M., Wasser, J.S., Luke, J.J., et al. Preliminary results from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immunother Cancer, 3(Suppl. 2), 2015, 07.
127. [127] Van der Burg, S.H., Marincola, F.M., Tumour immunology: what's beyond today's success in tumor immunology. Curr Opin Immunol 38 (2016), viii–x.
128. [128] Wang, E., Uccellini, L., Marincola, F.M., A genetic inference on cancer immune responsiveness. Oncoimmunology 1 (2012), 520–525.
129. [129] Seliger, B., The non-classical antigen of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors. Clin Transpl, 2013, 465–472.
130. [130] Carosella, E.D., Rouas-Freiss, N., Tronik-Le Roux, D., Moreau, P., LeMaoult, J., HLA-G: an immune checkpoint molecule. Adv Immunol 127 (2015), 33–144.
131. [131] Coulie, P.B., van den Eynde, Bj, van der Bruggen, P., Boon, T., Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14 (2014), 135–146.
132. [132] Chabanon, R.M., Pedrero, M., Lefebvre, C., Marabelle, A., Soria, J.C., Postel-Vinay, S., Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res 22 (2016), 4309–4321.
133. [133] Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
134. [134] Shen, M., Sun, Q., Wang, J., Pan, W., Ren, X., Positive and negative functions of B lymphocytes in tumors. Oncotarget 7 (2016), 55828–55839 epub ahead of print.
135. [135] Orecchioni, M., Bedognetti, D., Sgarrella, F., Marincola, F.M., Bianco, A., Delougu, L.G., Impact of carbon nanotubes and graphene on immune cells. J Transl Med, 21, 2014, 138.